RE:RE:RE:New presentation on the website if interestedEven the very largest of companies would know their exact cash positions within a few business days of year end. Given how small this company is, it's inconceivable that management doesn't know their exact cash position on a day-to-day basis. And there's no reason that they couldn't have provided an approximate cash position / runway as of December 31.
As for the CR, I asked Jon Patton about that last year and got a very unsatisfactory response. I had to ask twice, but I was told that it was "recorded" as having been a "complete response". I then followed up by asking why ONC no longer referenced the CR and was told to refer to the ESMO 2023 poster where one of the tumors "appeared" to show 100% shrinkage. I did not consider that to be a proper answer to my question, but gave up pursuing the matter. My best guess is that the patient was originally recorded by the PI as having a CR, but that that was later amended (for reasons unknown and unexplained). Perhaps on further examination, some cancer remained detectable. Who knows?